Real-life effectiveness of first-line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry

. 2020 Nov ; 11 (11) : 3346-3356. [epub] 20201005

Jazyk angličtina Země Singapur Médium print-electronic

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid33016001

Grantová podpora
MH CZ-DRO FNBr 65269705 Ministerstvo Zdravotnictví Ceské Republiky - International

BACKGROUND: Data regarding real-life effectiveness of any treatment may improve clinical decision-making. The aim of this study was to evaluate real-life effectiveness of tyrosin-kinase inhibitors, bevacizumab and pemetrexed as first-line treatments in patients with advanced/metastatic non-small cell lung cancer (NSCLC). METHODS: We analyzed data of 2157 patients of the Czech TULUNG Registry of patients with advanced/metastatic NSCLC who received modern-era treatments between 2011 and 2018. Patients treated with gefitinib, erlotinib, afatinib, bevacizumab (+ maintenance), pemetrexed (+ maintenance) as first-line therapy were included in the study. A systematic literature search separately identified clinical trials suitable for calculation of comparator pooled OS and PFS for each regimen. For each subgroup, basic characteristics and survival data (Kaplan-Meier estimates) are shown. We propose the "index of real-life effectiveness" (IRE), a ratio of real-life OS/PFS and comparator pooled OS/PFS. Univariate and multivariate logistic regression identified factors were associated with longer OS (ie, IRE>1.1). RESULTS: Survival analysis showed median OS of 23 months for erlotinib, 29.3 months for afatinib, 19.6 months for gefitinib, 12.2 months for pemetrexed, 17.5 months for pemetrexed maintenance, 15.8 months for bevacizumab and 15.8 months for bevacizumab maintenance. Calculated IREs for OS for the regimens were: erlotinib 1.013, afatinib 1.184, gefitinib 0.736, pemetrexed 1.188, pemetrexed maintenance 1.294, bevacizumab 1.178, and bevacizumab maintenance 1.189. Multivariate regression analysis showed that these factors were associated with longer OS: lower PS for afatinib; lower PS, absence of adverse events and female sex for bevacizumab; and lower PS and female sex for pemetrexed. CONCLUSIONS: This study clearly demonstrated that real-life effectiveness of certain treatment regimens may strongly differ in various populations/health care systems, and comparison between TULUNG data and pooled survival data from trials showed higher real-life effectiveness for most of the studied first-line regimens. Lower ECOG PS, younger age, female sex and adverse events were associated with longer survival in most regimens. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: Comparison between TULUNG data and pooled survival data from trials showed higher real-life effectiveness for most of the studied first-line regimens; for most regimens, lower ECOG PS, younger age, female sex and adverse events were associated with longer survival. WHAT THIS STUDY ADDS: Real-life effectiveness of certain treatment regimens may strongly differ in various populations/health care systems.

Zobrazit více v PubMed

Ferrara R, Mezquita L, Besse B. Progress in the management of advanced thoracic malignancies in 2017. J Thorac Oncol 2018; 13: 301–22. PubMed

Bratova M, Karlinova B, Skrickova J PubMed PMC

Cramer‐van der Welle CM, Schramel FMNH, van Leeuwen AS, Groen HJM, van de Garde EMW, for the Santeon NSCLC Study Group . Real‐world treatment patterns and outcomes of patients with extensive disease small cell lung cancer. Eur Respir J 2019; 54 (suppl 63): PA374. PubMed PMC

Bonotto M, Gerratana L, Iacono D PubMed PMC

Cramer‐van der Welle CM, Peters BJM, Schramel FMNH, Klungel OH, Groen HJM, van de Garde EMW for the Santeon NSCLC study group . Systematic evaluation of the efficacy‐effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer. Eur Respir J 2018; 52: 1801100. PubMed PMC

Lakdawalla DN, Shafrin J, Hou N PubMed

Halpin DM, Kerkhof M, Soriano JB, Mikkelsen H, Price DB. Eligibility of real‐life patients with COPD for inclusion in trials of inhaled long‐acting bronchodilator therapy. Respir Res 2016; 17: 120. PubMed PMC

Kawachi H, Fujimoto D, Morimoto T PubMed

Goldstraw P, Groome P. Lung and pleural tumours In: Sobin LH, Gospodarowicz MK, Wittekind C. (eds). UICC TNM Classification of Malignant Tumours, 7th edn Wiley‐Blackwell, Hoboken, NJ: 2009; 136–46.

Eisenhauer EA, Therasse P, Bogaerts J PubMed

Fetcko K, Lukas RV, Watson GA, Zhang L, Dey M. Survival and complications of stereotactic radiosurgery: A systematic review of stereotactic radiosurgery for newly diagnosed and recurrent high‐grade gliomas. Medicine 2017; 96: e8293. PubMed PMC

International Agency for Research on Cancer . The Netherlands. Global Cancer Observatory. https://gco.iarc.fr/today/data/factsheets/populations/528-the-netherlands-fact-sheets.pdf

Koopman JJ, Putter H. Regional variation in the practice of euthanasia and physician‐assisted suicide in The Netherlands. Neth J Med 2016; 74: 387–94. PubMed

Pardon K, Deschepper R, Vander Stichele R PubMed

Bergqvist M, Christensen HN, Wiklund F, Bergström S. Real world utilization of EGFR TKIs and prognostic factors for survival in NSCLC during 2010‐2016 in Sweden: A nationwide observational study. Int J Cancer 2020; 146: 2510–7. PubMed

Sun JM, Oh DY, Lee SH PubMed

Ciuleanu T, Brodowicz T, Zielinski C PubMed

Paz‐Ares LG, de Marinis F, Dediu M PubMed

Ramalingam SS, Dahlberg SE, Belani CP PubMed PMC

Zinner RG, Obasaju CK, Spigel DR PubMed PMC

Grønberg BH, Bremnes RM, Fløtten O PubMed

Park CK, Oh IJ, Kim KS PubMed

Paz‐Ares L, Mezger J, Ciuleanu TE PubMed

Rodrigues‐Pereira J, Kim JH, Magallanes M PubMed

Scagliotti GV, Parikh P, von Pawel J PubMed

Reck M, von Pawel J, Zatloukal P PubMed PMC

Sandler A, Gray R, Perry MC PubMed

Zhou C, Wu YL, Chen G PubMed

Patel JD, Socinski MA, Garon EB PubMed PMC

Johnson BE, Kabbinavar F, Fehrenbacher L PubMed

Camerini A, Chella A, Mazzoni F PubMed

Chang GC, Ahn MJ, Wright E PubMed

Kim Y, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM. Efficacy and safety of afatinib for EGFR‐mutant non‐small cell lung cancer, compared with gefitinib or erlotinib. Cancer Res Treat 2019; 51: 502–9. PubMed PMC

Yoshioka H, Shimokawa M, Seto T PubMed

Mok TS, Cheng Y, Zhou X PubMed

Hosomi Y, Morita S, Sugawara S PubMed

Yao ZH, Liao WY, Ho CC PubMed PMC

Maguire FB, Morris CR, Parikh‐Patel A PubMed PMC

von Verschuer U, Schnell R, Tessen HW PubMed

Park K, Tan EH, O'Byrne K PubMed

Wu YL, Zhou C, Hu CP PubMed

Wu YL, Zhou C, Liam CK PubMed

Zhou C, Wu YL, Chen G PubMed

An C, Zhang J, Chu H PubMed

Han B, Jin B, Chu T PubMed

Han JY, Park K, Kim SW PubMed

Inoue A, Kobayashi K, Maemondo M PubMed

Maemondo M, Inoue A, Kobayashi K PubMed

Patil VM, Noronha V, Joshi A PubMed PMC

Zhou C, Wu YL, Chen G PubMed

Rosell R, Carcereny E, Gervais R PubMed

Nakagawa K, Garon EB, Seto T PubMed

Kelly RJ, Shepherd FA, Krivoshik A, Jie F, Horn L. A phase III, randomized, open‐label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non‐small‐cell lung cancer. Ann Oncol 2019; 30: 1127–33. PubMed PMC

Mitsudomi T, Morita S, Yatabe Y PubMed

Mok TS, Wu YL, Thongprasert S PubMed

Wu YL, Cheng Y, Zhou X PubMed

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace